Free Trial
NYSE:HIMS

Hims & Hers Health Q3 2025 Earnings Report

Hims & Hers Health logo
$57.83 +3.07 (+5.60%)
Closing price 03:59 PM Eastern
Extended Trading
$57.77 -0.06 (-0.10%)
As of 04:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hims & Hers Health EPS Results

Actual EPS
N/A
Consensus EPS
$0.09
Beat/Miss
N/A
One Year Ago EPS
N/A

Hims & Hers Health Revenue Results

Actual Revenue
N/A
Expected Revenue
$578.99 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Hims & Hers Health Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Monday, November 3, 2025
Conference Call Time
5:00PM ET

Conference Call Resources

Hims & Hers Health Earnings Headlines

Why Hims & Hers Stock Slipped Today
Arizona-made nanochips the new millionaire maker?
George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.tc pixel
Buy HIMS Stock At $56?
See More Hims & Hers Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hims & Hers Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hims & Hers Health and other key companies, straight to your email.

About Hims & Hers Health

Hims & Hers Health (NYSE:HIMS) is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support. Through secure online questionnaires and video visits, patients receive personalized treatment plans covering conditions such as erectile dysfunction, acne, hair thinning, anxiety and depression. Hims & Hers also distributes supplements, vitamin formulations and topical solutions designed to complement its prescription offerings.

Founded in 2017 by Andrew Dudum and headquartered in San Francisco, Hims & Hers emerged as one of the first telehealth subscriptions focused on consumer-friendly branding and straightforward access to care. In July 2021, the company completed a business combination with a special purpose acquisition company, enabling its public listing on the New York Stock Exchange under the ticker HIMS. Since its inception, Hims & Hers has pursued strategic partnerships and acquisitions to expand its medical and technological capabilities.

Serving customers across the continental U.S., Hims & Hers continues to develop its digital care model by enhancing telehealth platform features, broadening its therapeutic categories and strengthening clinical support. Under the leadership of CEO Andrew Dudum and a team of healthcare and technology executives, the company aims to reduce barriers to medical access while driving scalable growth in the evolving virtual care market.

View Hims & Hers Health Profile

More Earnings Resources from MarketBeat